08/4-2009 THE NEVERENDING STORY By Dietmar Stöckl STT Consulting.

Slides:

Advertisements

Similar presentations

Updated Abstract T2:ERG Correlation with PCa Aggressiveness Conclusions T2:ERG Assay Clinical Performance The T2:ERG assay described has not been approved.

Advertisements

Introduction The incidence of prostate cancer in Asians is lower compared to the Westerners in men with PSA

Screening for Prostate Cancer Should we still test for PSA? Peter T. Scardino, M.D. and Andrew Vickers, Ph.D. Memorial Sloan-Kettering Cancer Center New.

Between-Method Differences in Prostate Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms C. Stephan, K. Siemβen, H. Cammann,

The PRIAS Study In Australia One Institution’s Experience Introduction PRIAS (Prostate cancer Research International: Active Surveillance – NTR1718) is.

Carcinoma of the Prostate By: Ishan Parikh. Background on Cancer  Oldest information dates back to 3000 BC, Egyptian textbook on trauma surgery – “There.

Prevention Strategies Rajesh G. Laungani MD Director, Robotic Urology Chairman, Prostate Cancer Center Saint Joseph’s Hospital, Atlanta.

Otis W. Brawley, M.D. Chief Medical and Scientific Officer Executive Vice President American Cancer Society Professor of Hematology, Medical Oncology,

Prostate Cancer in 2009, part I. Now and the future! Why we have ‘Active surveillance, its purpose, its outcome and other matters. Monique J. Roobol, PhD,

Comparison of Outcomes between Brachytherapy and Intensity Modulated Radiotherapy in High Risk Prostate Cancer M. A. Weller, C. A. Reddy, J. Kittel, K.

RISK OF NON SIGNIFICANT PROSTATE CANCER IN PROSTATE CANCER PATIENTS DIAGNOSED BY AN EXTENDED PROSTATE NEEDLE BIOPSY PROCEDURE AND TREATED BY RADICAL PROSTATECTOMY.

Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.

PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition May 15, 2010.

EDRN Approaches to Biomarker Validation DMCC Statisticians Fred Hutchinson Cancer Research Center Margaret Pepe Ziding Feng, Mark Thornquist, Yingye Zheng,

Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.

A GENERAL OVERVIEW OF PROSTATE CANCER. PROSTATE CANCER 101 SPONSORED BY THE CALIFORNIA STATE PROSTATE CANCER COALITION AND THE NATIONAL ALLIANCE OF STATE.

The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.

Routine PSA: Evaluating the Evidence Sheldon Greenfield, MD Health Policy Research Institute University of California, Irvine October 23, 2012.

All about PSA (not Pharmaceutical Society of Australia)

Overdetection of prostate cancer ESMO Brussel 2007 Chris H.Bangma Erasmus University Medical Centre Rotterdam, The Netherlands.

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Fifth Annual African-American Prostate Cancer Disparity Summit September 24, 2009 Christine.

Prostate Cancer Screening in African American Men Mark H. Kawachi, MD FACS Director, Prostate Cancer Center City of Hope, National Medical Ctr.

PCa Screening New Areas of Research Francesco Montorsi Milan.

Prevention with Finasteride Ian M. Thompson, MD October, 2009.

Prostate Cancer Coalition of NC A statewide collaborative effort by concerned organizations and individuals to support awareness, early detection, and.

Management of Senior Adults with Prostate Cancer Patients’ Perspectives Louis Denis - Europa Uomo Milan,

A prospective randomized trial

MpMRI in Prostate cancer A Urologist’s Perspective Diagnosis Treatment Choice Surgical Planning Dr. Peter Heathcote, Adjunct Professor APCRC-Q QUT, Senior.

Active surveillance in prostate cancer Dr John Yaxley Urological & robotic surgeon.

Prostate Cancer Management: A Guide for Patients and Caregivers

Per-Anders Abrahamsson, Department of Urology Malmö University Hospital Sweden EAU, Berlin, March 24, 2007 What´s New in Prostate Cancer?

Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.

V. Scattoni mpMRI of the prostate: Does it change indications for biopsy and repeat biopsy?

Understanding Prostate Myths

South West Public Health Observatory South West Regional Public Health Group Prostate cancer in England and the South West Sean McPhail 1, Paul Eves 1,

PSA screening Cost Conscious Project Kristopher Huston January 2016.

Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.

Date of download: 7/6/2016 From: Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies: Model Estimates.

CHAPS - The Men’s Health Charity PROSTATE CANCER To Screen or Not To Screen - That is the Only Question Chris Booth MBBS, FRCS Emeritus.

IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.

Yuna Jo. Introduction Prostate cancer (PCa) continues to burden the Western world with its high rates of incidence and mortality despite the.

Network meeting Taunton Rugby club January 20th

Volume 56, Issue 5, Pages (November 2009)

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit Pim J. van Leeuwen, David Connolly, Anna.

74-year-old man with stage T2a Gleason score prostate cancer (prostate specific antigen = ng/mL) in right transition zone (TZ) with history.

Copyright © 1998 American Medical Association. All rights reserved.

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Comparison of PSA Values of Prostate Cancer Patients Before, During and After Prostate Biopsy Using Gleason Score Mehmet KILINC1, Yunus Emre GOGER1, Hasan.

International Neurourology Journal 2013;17:73-77

In Focus 6 Spotlight on Specific Cancers TANYA

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Volume 61, Issue 3, Pages (March 2012)

Volume 63, Issue 4, Pages (April 2013)

Testosterone Deficiency

Towards Early and More Specific Diagnosis of Prostate Cancer

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 56, Issue 2, Pages (August 2009)

Volume 63, Issue 6, Pages (June 2013)

Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions Anwar R. Padhani, Jeffrey Weinreb, Andrew.

Volume 66, Issue 6, Pages (December 2014)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 58, Issue 1, Pages (July 2010)

European Urology Oncology

Volume 75, Issue 4, Pages (April 2019)

Management of Prostate Cancer: Global Strategies

Volume 54, Issue 3, Pages (September 2008)

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.

Longer testing interval may impact the outcome of a prostate biopsy following the index PSA test due to longer time for a potential tumour to grow from.

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Presentation transcript:

08/ THE NEVERENDING STORY By Dietmar Stöckl STT Consulting

Tin Can 5 - The Neverending Story 2 Cutoffs and [Non]Standardization

Tin Can 5 - The Neverending Story 3 tPSA cutoff Abbott % Free PSA Physician Monograph

Tin Can 5 - The Neverending Story 4 tPSA cutoff and standardization Although most clinicians are familiar with the fact that different tPSA assays produce different results (let’s just accept that for now#), they may not be aware that restandardization from a historical standard to the WHO calibration causes a shift in mass units, which yields a potential for underestimating tPSA values. If this shift is not fully appreciated, especially with respect to the tPSA threshold value (“cutoff”) for biopsy, a resulting decrease in PCa detection may produce life-altering consequences for individual patients. Jansen FH, Roobol M, Bangma CH, van Schaik RHN. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem 2008;54: #

Tin Can 5 - The Neverending Story 5 tPSA cutoff and standardization The finding of a decrease in cancer detection caused by application of the WHO 96/670 calibration (note: 20% lower than Hybritech) may also have positive implications in light of the current discussions on limiting PCa overdetection and subsequent overtreatment. Because the group of missed cancers contains significantly fewer tumors with a high stage or a high Gleason score and more tumors with favorable characteristics, missing these cancers may not have clinical consequences and so may limit the overdetection and overtreatment of PCa. Krijg nou wat! Jansen FH, Roobol M, Bangma CH, van Schaik RHN. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem 2008;54:

Tin Can 5 - The Neverending Story 6 Editorial to the Jansen publication We suggest an additional possibility, to abandon the cutpoint of 3 or 4 µg/L altogether. Vickers AJ, Lilja H. Cutpoints in Clinical Chemistry: Time for Fundamental Reassessment. Clin Chem 2009;55:15-7.

Tin Can 5 - The Neverending Story 7 “In the end” Eminent scientist What is the greatest risk factor for prostate cancer? Visiting your urologist! Audience laughs